

Press Release

Strides Announces Q1 '2011 Financial Results

Delivers strong Revenue and EBIDTA Continued growth momentum in Specialty business

Bangalore, April 25, 2011: Strides Arcolab (Strides) today announced strong revenue and EBIDTA numbers for Q1 '2011.

- Consolidated revenue at Rs 4,981 Mn, **31% Growth** over Q1'10 (Rs 3,815 Mn)
- Consolidated EBITDA at Rs 1,023 Mn, **19% Growth** over Q1'10 (Rs 859 Mn)
- Specialty business **grew by 93%** over corresponding quarter of last year.
- US FDA approval for new Sterile Injectable facility in Bangalore
- Received approval for commercializing of Vancomycin (lyophilized format) and another Liquid Injectable product from the new Sterile facility
- Commenced sales to US Market from the new Sterile facility
- Received European approval for 'Carboplatin', first oncology product approval in Europe
- 9 filings and 3 approvals from regulated markets and 6 filings and 21 approvals from emerging markets

A detailed analysis of the results is appended as an attachment to this press release.


"In the backdrop of a strong Q1 '2011, the recent US FDA approval for the new state-of-the-art sterile facility in Bangalore and the first approval for an oncology product from Europe, we expect a further scale up in our growth momentum, particularly in the specialty business," said Arun Kumar, Vice Chairman & Group CEO, Strides Arcolab Limited.

About Strides Arcolab

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India, that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the Company's website at www.stridesarco.com.



For further information, please contact:

<p><u>Strides</u></p> <p>Mr. T.S. Rangan, Group CFO +91 80 66580115</p> <p><u>Investors:</u></p> <p>Mr. Kannan. N - +98450 54745 Mr Ajay Singh - +91 80 66580813</p> <p><u>Media:</u></p> <p>Melissa Arulappan - +91 98450 22389</p>	<p><u>PR Consultancy</u></p> <p>Corporate Voice/Weber Shandwick</p> <p>Mahesh Nair, +91 9880376648 maheshn@corvoshandwick.co.in</p> <p>Hiba Kunil +91 98807 26372 hiba@corvoshandwick.co.in</p>
--	--

